Javelin Biotech
Javelin Biotech specializes in humanized preclinical drug discovery platforms that merge human tissue chips and digital twin technology to develop better medicines faster. With a rich history of groundbreaking initiatives, the company aims to provide human-specific, high-content data for drug development, reducing reliance on animal studies and accelerating the path to market.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Liver tissue chip platform
Disposable thermoplastic liver tissue chips designed for continuous recirculating culture to support long-term metabolically active hepatic microphysiological studies and longitudinal data collection.
Incubator-compatible perfusion controller
Standalone controller that perfuses multiple tissue chips within a CO2 incubator environment, enabling easy insertion/removal of chips and operation without external tubing or pumps.
Qualified cell kits (biokits)
Pre-packaged kits including qualified primary human cell vials, multiple chips, and certificates of analysis providing characterization data on morphology and liver-specific biomarkers.
Digital twin software with hepatic clearance module
Software platform that supports experiment design, multi-modal data analysis, and translational prediction workflows; includes a hepatic clearance module that converts chip-derived data into human PK estimates.
Starter package: chips, controller, qualified cells, protocols, and training
Integrated starter offering that includes tissue chips, controller hardware, qualified cells, established protocols, and on-site training to accelerate initial deployment.
Liver tissue chip platform
Disposable thermoplastic liver tissue chips designed for continuous recirculating culture to support long-term metabolically active hepatic microphysiological studies and longitudinal data collection.
Incubator-compatible perfusion controller
Standalone controller that perfuses multiple tissue chips within a CO2 incubator environment, enabling easy insertion/removal of chips and operation without external tubing or pumps.
Qualified cell kits (biokits)
Pre-packaged kits including qualified primary human cell vials, multiple chips, and certificates of analysis providing characterization data on morphology and liver-specific biomarkers.
Digital twin software with hepatic clearance module
Software platform that supports experiment design, multi-modal data analysis, and translational prediction workflows; includes a hepatic clearance module that converts chip-derived data into human PK estimates.
Starter package: chips, controller, qualified cells, protocols, and training
Integrated starter offering that includes tissue chips, controller hardware, qualified cells, established protocols, and on-site training to accelerate initial deployment.
Services
Hands-on training and implementation services to integrate tissue chips, controllers, qualified cells, and software into customer workflows.
Collaborative development and support for assays and study designs addressing lead optimization, pharmacokinetics, toxicology, drug delivery, disease modeling, and target validation/de-risking.
Services to design experiments, process multi-modal chip data, and generate translational predictions using machine learning and mechanistic models.
Hands-on training and implementation services to integrate tissue chips, controllers, qualified cells, and software into customer workflows.
Collaborative development and support for assays and study designs addressing lead optimization, pharmacokinetics, toxicology, drug delivery, disease modeling, and target validation/de-risking.
Services to design experiments, process multi-modal chip data, and generate translational predictions using machine learning and mechanistic models.
Expertise Areas
- Microphysiological systems (MPS) and organ-on-chip development
- In vitro pharmacology and translational preclinical testing
- Pharmacokinetics and drug-drug interaction (DDI) modeling
- Computational biology and digital twin development
Key Technologies
- Organ-on-chip / microphysiological systems
- Milli-fluidic and microfluidic recirculating platforms
- Primary human hepatocyte and multicellular primary cell culture
- Machine learning combined with mechanistic (systems) modeling (digital twin)
News & Updates
Javelin Biotech appointed Dr. Robin Robinson to its board, reinforcing human-centric drug discovery aligned with the FDA Modernization Act 3.0.
New initiative aims to reduce use of animals in NIH-funded research.
FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
FDA takes a significant step towards modernizing drug testing by phasing out animal requirements for monoclonal antibodies and other drugs.
A translational experimental system to predict clinical clearance values of both perpetrator and victim drugs.
Development of a pathway-based similarity measurement to assess the human relevance of preclinical models.
Joint publication with Pfizer in the AAPS journal.
Javelin Biotech appointed Dr. Robin Robinson to its board, reinforcing human-centric drug discovery aligned with the FDA Modernization Act 3.0.
New initiative aims to reduce use of animals in NIH-funded research.
FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
FDA takes a significant step towards modernizing drug testing by phasing out animal requirements for monoclonal antibodies and other drugs.
A translational experimental system to predict clinical clearance values of both perpetrator and victim drugs.
Development of a pathway-based similarity measurement to assess the human relevance of preclinical models.
Joint publication with Pfizer in the AAPS journal.